PHARMACOKINETICS & TOLERANCE OF GANCICLOVIR IN HIV INFECTED CHILDREN

药代动力学

• 批准号: 6274832
• 负责人: JOSEPH CHURCH
• 金额: $ 3.67万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274832
• 关键词: AIDS therapy; HIV infections; Herpesviridae disease; adolescence (12-20); child (0-11); clinical research; clinical trials; cytomegalovirus; drug administration rate /duration; drug adverse effect; drug screening /evaluation; drug tolerance; ganciclovir; human immunodeficiency virus; human subject; human therapy evaluation; opportunistic infections; oral administration; pediatric AIDS; pediatric pharmacology; pharmacokinetics

Individuals between two weeks to twenty years of age who have an HIV and cytomegalovirus are enrolled in this study to evaluate the safety and side effects of a new oral medication, ganciclovir. The purpose of this study is to determine if an oral form of ganciclovir can be tolerated when given for 24 weeks to HIV infected infants and children with CMV infection and to determine the maximum tolerable dose and side effects of oral ganciclovir.

两周至二十岁之间感染艾滋病毒且 巨细胞病毒纳入本研究以评估其安全性和 一种新的口服药物更昔洛韦的副作用。 这样做的目的 研究的目的是确定口服更昔洛韦是否可以耐受 给感染 HIV 的婴儿和患有 CMV 的儿童服用 24 周 感染并确定最大耐受剂量和副作用 口服更昔洛韦。